New treatment approach for kidney cancer using a dual inhibitor
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer
This study is testing a new treatment for clear cell kidney cancer that aims to stop the cancer from growing by using a special drug that targets certain proteins, and it's designed for patients who haven't had success with standard therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kuda Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project ID | NIH-10708992 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that is resistant to standard therapies. The approach involves using a dual inhibitor that targets specific proteins involved in cancer progression and induces a form of cell death known as ferroptosis. By inhibiting these proteins, the treatment aims to reduce tumor growth and improve patient outcomes. The research includes both laboratory and animal studies to evaluate the effectiveness and safety of the new compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who have not responded to conventional treatments.
Not a fit: Patients with other types of kidney cancer or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced kidney cancer.
How similar studies have performed: Previous research has shown promise in targeting HIF proteins in kidney cancer, indicating that this approach could be a significant advancement in treatment.
Where this research is happening
Salt Lake City, UNITED STATES
- Kuda Therapeutics, INC. — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Lippert, Robert — Kuda Therapeutics, INC.
- Study coordinator: Lippert, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.